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Paracoccidioidomycosis (PCM) is a systemic granulomatous disease caused by the dimorphic fungus Para-
coccidioides brasiliensis. Anti-PCM vaccine formulations based on the secreted fungal cell wall protein (gp43)
or the derived P10 sequence containing a CD4 T-cell-specific epitope have shown promising results. In the
present study, we evaluated new anti-PCM vaccine formulations based on the intranasal administration of P.
brasiliensis gp43 or the P10 peptide in combination with the Salmonella enterica FliC flagellin, an innate
immunity agonist binding specifically to the Toll-like receptor 5, in a murine model. BALB/c mice immunized
with gp43 developed high-specific-serum immunoglobulin G1 responses and enhanced interleukin-4 (IL-4) and
IL-10 levels. On the other hand, mice immunized with recombinant purified flagellins genetically fused with
P10 at the central hypervariable domain, either flanked or not by two lysine residues, or the synthetic P10
peptide admixed with purified FliC elicited a prevailing Th1-type immune response based on lung cell-secreted
type 1 cytokines. Mice immunized with gp43 and FliC and intratracheally challenged with P. brasiliensis yeast
cells had increased fungal proliferation and lung tissue damage. In contrast, mice immunized with the chimeric
flagellins and particularly those immunized with P10 admixed with FliC reduced P. brasiliensis growth and lung
damage. Altogether, these results indicate that S. enterica FliC flagellin modulates the immune response to P.
brasiliensis P10 antigen and represents a promising alternative for the generation of anti-PCM vaccines.
Paracoccidioidomycosis (PCM) is a granulomatous disease
caused by the thermodimorphic fungus Paracoccidioides bra-
siliensis, which is prevalent in Brazil and other Latin American
countries (5, 6, 33). Some individuals develop one of the two
main clinical forms of PCM. The acute form is characterized by
impaired cellular immunity, negative delayed-type hypersensi-
tivity reactions, increased systemic proliferation of the fungus,
and high mortality rate. The chronic form, ranging from mild
to severe chronic disease, shows exacerbated host cellular im-
mune responses and formation of granulomas containing fun-
gal cells and may evolve to develop extensive sequelae, includ-
ing fibrotic lesions and impairment of lung function (33, 39).
Vaccines against PCM are still not available for human use,
but promising formulations have been experimentally tested
during the last few years. Irradiated P. brasiliensis or cellular
antigens fractionated by anion-exchange chromatography con-
ferred partial protection against fungal proliferation in the
murine model (11). The extracellular gp43 glycoprotein, the
major diagnostic antigen of P. brasiliensis, is the most inten-
sively studied component aimed at a vaccine for PCM control.
Previous reports have shown that mice immunized with the
purified protein, DNA, or anti-idiotypic monoclonal antibody
were partially protected against challenges by P. brasiliensis
(28, 36, 37, 40). A 15-amino-acid peptide (QTLIAIHTLAIRY
AN), designated P10, contains the gp43 immunodominant
CD4 T-cell-specific epitope presented by major histocompat-
ibility complex class II molecules from three different mouse
haplotypes (37) and most human HLA-DR alleles (17, 18).
Indeed, parenteral immunization with P10 in complete Freund
adjuvant (CFA), or in the form of a truncated multiple-antigen
peptide (MAP) complex, induced protective Th1 cellular im-
mune responses in mice against intratracheal (i.t.) challenge
with a virulent P. brasiliensis isolate (37, 38, 41).
The rational use of vaccines has been significantly improved
after elucidation of innate immune mechanisms in mammalian
cells. The recognition of distinct pathogen-associated molecu-
lar patterns by members of the Toll-like receptor (TLR) family
initiates a signaling cascade mediated by adaptor proteins,
including MyD88 and interleukin-1 (IL-1) receptor-associated
kinase, that culminates in the production of proinflammatory
cytokines, such as tumor necrosis factor alpha and IL-12, and
increased expression of cell surface molecules involved in
epitope presentation by antigen-presenting cells (APC) (1, 19).
Proper APC activation by TLR agonists represents a key step
for an effective adaptive immune response induced by patho-
gens or vaccines and explains, at least in part, the marked
adjuvant effects of several bacterial molecules, including lipo-
polysaccharides, lipoproteins, peptidoglycan fragments, and
flagellins (2).
Flagellin, the structural subunit of bacterial flagellum, is a
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highly conserved protein that induces TLR5-dependent in-
flammatory responses and exerts strong adjuvant effects on
both antibody and cellular immune responses (12, 13, 30).
Flagellin has been successfully used as a vaccine adjuvant to
generate antigen-specific antibodies and T cells either when
administered to mice as the native purified protein (4, 14, 20,
27) or as a hybrid protein genetically fused to the target anti-
gen (10, 15, 16). Additionally, in contrast to other vaccine
adjuvants, such as CFA, flagellin may exert strong adjuvant effects
following administration through mucosal routes (14, 27).
In the present study, we have evaluated the adjuvant effects
and protective efficacy of intranasal (i.n.) anti-PCM vaccine
formulations based on Salmonella enterica serovar Dublin FliC
flagellin and purified recombinant P. brasiliensis gp43 or the
synthetic P10 peptide. In addition, recombinant chimeric
flagellins genetically fused to P10 were also tested as potential
anti-PCM vaccine antigens. The results demonstrate that S.
enterica FliC flagellin modulates the murine immune system
favoring either the generation of antibodies (gp43 plus FliC) or
activation of cellular immune responses. In accordance with
the administered vaccine formulation, mice challenged with P.
brasiliensis were differentially protected against exacerbated
fungal proliferation. The present results indicate that Salmo-
nella FliC has an important role in the generation of mucus-
delivered anti-P. brasiliensis peptide-based vaccine formula-
tions. Furthermore, flagellin-based adjuvants may contribute
to the understanding of immune mechanisms involved in PCM
development.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. The bacterial strains and
plasmids used in this study are described in Table 1. The strain Salmonella
enterica pv. Dublin SL5928 is a nonflagellated aroA attenuated vaccine strain
(34). Salmonella pv. Dublin SL5930 is a SL5928 derivative transformed with the
plasmid pLS408 encoding the gene fliCd, originally derived from Salmonella
enterica serovar Mu¨nchen, with a 48-bp deletion generated after removal of a
EcoRV-EcoRV fragment from the central hypervariable domain leading to a
single EcoRV site used for in-frame insertion of nucleotide sequences encoding
heterologous epitopes. All S. Dublin and Escherichia coli strains were routinely
cultivated at 37°C with shaking (200 rpm) in Luria-Bertani (LB) broth or on LB
agar plates supplemented with ampicillin (100 g/ml).
Fungal strain. The virulent P. brasiliensis Pb18 strain was maintained by
weekly passages on solid Sabouraud medium at 36°C. Before experimental in-
fection, cultures were grown in modified McVeigh-Morton medium at 36°C for
5 to 7 days (31). The fungal cells were washed in phosphate-buffered saline (PBS;
pH 7.2) and counted in a hemocytometer. The upper part of cell suspensions that
contained isolated or single budding cells was used in the infection experiments
and for cell counting after decanting the clusters of yeast cells. The viability of
fungal suspensions was determined by staining with trypan blue (Sigma, St.
Louis, MO) and was always higher than 90%. The virulence of the Pb18 strain
was checked in each experiment by infecting BALB/c mice i.t. and recovering the
yeast cells from the infected organs.
Generation of hybrid flagellins genetically fused to P10. Chimeric Salmonella
flagellins were generated after cloning the complementary oligonucleotides into
the single EcoRV site of the pLS408-clonded FliC-encoding gene (24). Comple-
mentary 45-base oligonucleotides P10fw (5-GAA ACC CTG ATT GCG ATT
CAT ACC CTG GCG ATT CGC TAT GCG AAC-3) and P10rv (5-CTT TGG
GAC TAA CGC TAA GTA TGG GAC CGC TAA GCG ATA CGC TTG-3),
encoding P10 (QTLIAIHTLAIRYAN), were melted at 65°C, annealed by slowly
cooling at room temperature, and blunt end ligated with T4 DNA ligase to the
EcoRV-cleaved pLS408. The same procedure was repeated with P10KKfw and
P10KKrv oligonucleotides that, in addition to the sequence encoding the P10
peptide, carried on both 5 and 3 ends the sequence “AAA AAA,” encoding two
additional lysine residues flanking the heterologous epitope (KKQTLIAIHTLA
IRYANKK) genetically fused to FliC flagellin, in order to improve the proteo-
lytic processing by cathepsin B and enhance epitope processing and presentation
by APC (42). The resulting plasmids (pLSP10, encoding the recombinant FliC
genetically fused to P10, and pLSP10L, in which the P10 peptide is flanked by
two lysine residues) were introduced by electroporation (using 0.2-cm electro-
poration cuvettes at 600, 25 F, and 1.75 kV; Gene-Pulser [Bio-Rad, Hercules,
CA]) into E. coli strain DH5, and transformants were selected on LB plates
containing ampicillin. Recombinant plasmids with the right inserts were screened
by EcoRV digestion and sequenced with the BigDye Terminator DNA sequenc-
ing kit (PerkinElmer Applied Biosystems, Waltham, MA) using a 15-mer primer
(5-CCA GGT GCC TAC ACC CCG-3) corresponding to a sequence located 50
bp downstream of the EcoRV insertion site in pLS408. The recombinant plas-
mids encoding fliCd genetically fused to P10 or the sequence flanked by two
additional lysines were named pLSP10 and pLSP10L, respectively. Finally, the
plasmids pLSP10 and pLSP10L were introduced into the flagellin-negative S.
Dublin SL5928 strain by electroporation and the recombinant vaccine strains
named SLP10 and SLP10L, respectively.
Purification of Salmonella flagellins. Salmonella flagellins, comprising FliC,
FliCd-P10, and FliCd-P10L, were harvested from the respective S. Dublin
SL5930, SLP10, and SLP10L strains cultivated in LB broth, according to a
previously described procedure (4). Briefly, flagellins were obtained after cen-
trifugation of cells, suspended in PBS (pH 7.4), and sheared in a bench mixer at
maximal speed (a 1-min treatment repeated three times), followed by another
centrifugation step to remove the bacterial cells. Broken flagellar fragments were
precipitated with acetone, suspended in PBS, and finally, submitted to heat
treatment (65°C for 30 min) to dissociate the flagellin monomers. The protein
concentration was determined using the bicinchoninic acid assay (Pierce, Rock-
ford, IL), and the purity of the protein preparations was monitored by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Removal of
contaminating lipopolysaccharide was accomplished with Detoxi-Gel columns
(Pierce, Rockford, IL) according to the manufacturer’s instructions. Endotoxin
levels, determined with the chromogenic Limulus amebocyte lysate assay (Cam-
brex Bio Science, Walkersville, MD), were always below 3.0 endotoxin units/g
of protein.
Purification of gp43 antigen. P. brasiliensis Pb18 was cultivated in yeast Sab-
ouraud liquid medium for 7 days at 36°C with shaking. The culture was inacti-
vated by adding 0.2 g of thimerosal (Merthiolate)/liter filtered through filter
paper, concentrated in a vacuum at 40°C, and dialyzed against distilled water.
Purification of gp43 was obtained by affinity chromatography on Affi-Gel (Bio-
Rad, Hercules, CA) bound to anti-gp43 monoclonal antibody as previously
described (29). Elution was carried out with 50 mM citrate buffer, pH 2.8. The
eluate was concentrated in Amicon 10K cells, and the antigen preparation was
monitored by SDS-PAGE revealed with silver staining. The protein content was
determined by the Bradford method (3).
TABLE 1. Strains and plasmids used in this study
Strain or plasmid Relevant characteristic(s) Source orreference
Strains
Salmonella Dublin
SL5928 aroA his fliC::Tn10 24
SL5930 SL5928 with pLS408; mobile 24
SLP10 SL5928 with pLSP10 This study
SLP10L SL5928 with pLSP10L This study
P. brasiliensis




pLS408 pUC19 derivative carrying the
fliCd gene from S. Mu¨enchen
with 48-bp deletion in the
hypervariable region of the
FliC gene bla
24
pLSP10 pLS408 derivative with a 45-bp
insert encoding the P10 epitope
This study
pLSP10L pLS408 derivative with a 57-bp
insert encoding the P10 epitope
with two flanking lysines
This study
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SDS-PAGE. SDS-PAGE was performed following standard procedures using
a Mini-Protean II vertical electrophoresis unit (Bio-Rad, Hercules, CA). Pro-
teins sorted in 12% polyacrylamide gels were stained with Coomassie blue.
Immunization regimens. Isogenic pathogen-free 8- to 12-week-old male
BALB/c (H-2d) mice were supplied by the Isogenic Mouse Breeding Facility of
the Department of Parasitology, Institute of Biomedical Sciences (ICB), Uni-
versity of Sa˜o Paulo (USP). Animal handling was carried out in accordance with
the Brazilian code for use of laboratory animals and was approved by the Ethics
Committee of ICB, USP. Groups of 8 to 10 animals were immunized via the i.n.
route with 15 g of each fusion protein (FliCd-P10 or FliCd-P10L) or with a
mixture of 20 g P10 peptide or 25 g gp43 protein with 5 g FliC flagellin.
Control groups were immunized with sterile PBS, 25 g of gp43, 5 g FliC
flagellin, or 20 g of P10 peptide in Freund adjuvant 1:1 (vol/vol). The formu-
lations were instilled into the nostrils (5 l/nostril) with a micropipette on days
0, 21, and 28. The control group immunized with P10 in Freund adjuvant
received 1 dose (20 g of the peptide plus CFA in a total volume of 50 l) via
the subcutaneous route (rear footpads) and 3 doses (20 g of the peptide in
incomplete Freund adjuvant; a total volume of 200 l) administered intraperi-
toneally at 1-week intervals. Immune responses were evaluated 7 days after
immunization and 60 days after fungal challenge.
Challenge with P. brasiliensis yeast cells. Eighty days after the last immuniza-
tion, mice were inoculated i.t. with 3  105 yeast cells/animal of virulent P.
brasiliensis Pb18 grown on Sabouraud agar and suspended in sterile saline
(0.85% NaCl). A maximum of 50 l was inoculated per mouse. Briefly, mice were
anesthetized intraperitoneally with 200 l of a solution containing 80 mg of
ketamine/kg of body weight and 10 mg/kg of xylazine (both from Unia˜o Química
Farmaceˆutica, Brazil). After approximately 10 min, the necks were extended and
the tracheas exposed at the level of the thyroid. For the i.t. inoculation, a
26-gauge needle was used and the incisions were sutured, right afterwards, with
a 5 to 0 silk thread.
Fungal burden in organs of infected mice. Mice were sacrificed 60 days after
i.t. infection, and the fungal burden was measured by CFU. Sections of the lungs,
livers, and spleens were removed, weighed, and homogenized using a tissue
grinder in 10 ml of sterile PBS. The corresponding pellets were resuspended and
homogenized each in 1 ml of PBS. A 100-l sample of this suspension was plated
on solid brain heart infusion medium supplemented with 4% fetal calf serum
(Gibco, NY), 5% spent P. brasiliensis (strain 192) culture supernatant, strepto-
mycin/penicillin (10 IU/ml) (Cultilab, Brazil), and cycloheximide (500 mg/ml)
(Sigma, St. Louis, MO). Petri dishes were incubated at 36°C for at least 20 days,
and colonies were counted (1 colony  1 CFU) (35).
Lung histopathology. Following immunization with different vaccine formula-
tions, BALB/c mice were i.t. infected and sacrificed after 2 months. The lungs
were excised, fixed in 10% buffered formalin, and embedded in paraffin for
sectioning. The sections were stained with hematoxylin-eosin and examined
microscopically (Optiphot-2; Nikon, Tokyo, Japan).
Cytokine determination by enzyme-linked immunosorbent assay. Cytokine
analysis was performed 7 days after the immunizations and 2 months after
infection of the animals. Lung sections (right and left alternating) of mice were
homogenized in 2 ml of PBS in the presence of protease inhibitors (Boehringer
Mannheim, Indianapolis, IN). The homogenates were centrifuged, and the su-
pernatants were frozen at 80°C until tested. The supernatants were assayed for
IL-4, IL-10, IL-12, and gamma interferon (IFN-	) using enzyme-linked immu-
nosorbent assay kits (BD PharMingen, San Diego, CA). The detection limits of
such assays were as follows: 7.8 pg/ml for IL-4, 31.25 pg/ml for IL-10 and IFN-	,
and 62.5 pg/ml for IL-12p40, as indicated by the manufacturer.
Statistical analysis. Data were analyzed by one-way analysis of variance and
Student’s t test followed by Tukey’s honestly significant difference test and
Dunnett’s multiple comparison tests to compare the differences between the
mean values of the immunization groups studied.
RESULTS
Mice immunized with purified gp43 admixed with Salmo-
nella FliC flagellin develop specific antibody responses. Male
BALB/c mice received three i.n. doses of purified gp43 alone
or admixed with purified FliC, and the serum gp43-specific
immunoglobulin G (IgG) responses were measured 7 days
after the last immunization and 60 days after the i.t. challenge
with P. brasiliensis strain Pb18. Enhanced gp43-specific IgG1
antibodies were detected in noninfected mice immunized with
the FliC-containing vaccine formulation (IgG1 titer, 3,804 

28.83) but not in animals immunized with purified gp43 (IgG1
titer, 207 
 75.12) (Fig. 1A). A further 6.2-fold increase in the
anti-gp43 serum IgG1 was detected in vaccinated mice follow-
ing challenge with Pb18 (average IgG1 titer, 23,924
 21.00) in
mice immunized with the FliC-containing vaccine formulation
FIG. 1. Characterization of the specific serum IgG subclass response elicited in mice i.n. immunized with gp43 or gp43 admixed with FliC.
(A) Anti-gp43-specific IgG subclass detected 1 week after the last immunization dose. (B) Anti-gp43-specific IgG subclass detected in vaccinated
mice 2 months after i.t. challenge with the Pb18 strain. gp43, mice immunized with 3 doses of purified gp43; gp43  FliCd, mice immunized with
purified gp43 admixed with FliC. For the other groups (FliCd, FliCd-P10, FliCd-P10L, and P10  FliCd), a gp43-specific antibody response was
not detected. Values are means of endpoint titers plus standard deviations for serum pools (n  8) prepared from each mouse group. Data are
representative of two independent experiments with similar results. The IgG1/IgG2a ratio of each immunization group is indicated at the top of
the figure. Asterisks indicate a statistically significant difference observed between mice immunized with gp43 and mice immunized with gp43
admixed with FliC (P  0.01).
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(Fig. 1B). Determination of the specific IgG subclasses elicited
in mice immunized with gp43/FliC vaccine formulation re-
vealed a biased type 2 response with IgG1/IgGa ratios of 7.5
and 14.3 before and after the fungus challenge, respectively
(Fig. 1). These results indicate that Salmonella FliC flagellin
acted as a strong antibody-inducing adjuvant when admixed
with purified P. brasiliensis gp43 following mucosal administra-
tion in BALB/c mice.
Generation of vaccine formulations based on P10 geneti-
cally fused or admixed with Salmonella FliC. Additional anti-P.
brasiliensis vaccine formulations were tested and employed the
P10 peptide in combination with FliC. The first approach re-
lied on the generation of hybrid flagellins in which the P10
minigene was wedged in frame at the central hypervariable
domain of FliC, a permissive insertion site that did not affect
both the inflammatory and adjuvant properties of Salmonella
flagellin (Fig. 2A). The resulting recombinant S. Dublin SLP10
(encoding FliCd-P10) and SLP10L (encoding FliCd-P10L)
strains were nonmotile in semisolid agar plates but expressed
abundant extracellular flagella composed by hybrid flagellins
with slightly altered molecular weights, as demonstrated by
SDS-PAGE of purified flagella (Fig. 2B). After purification,
the flagellin preparations were 95% pure and endotoxin lev-
els were below 3.0 endotoxin units/g of protein. Another
P10-based vaccine formulation involved admixing of purified
native FliC (5 g) with the synthetic P10 peptide (20 g).
Cytokine expression patterns in mice immunized with dif-
ferent vaccine formulations containing Salmonella FliC flagel-
lin. The cytokine (IL-4, IL-10, IL-12, and IFN-	) expression
pattern in the lung tissue of mice immunized with the different
vaccine formulations was determined 7 days after the last im-
munization dose and 60 days following the i.t. challenge with P.
brasiliensis Pb18 yeast forms. As shown in Table 2, the concen-
trations of IL-4 and IL-10 were low in lung extracts from all
immunized groups except in animals immunized with purified
gp43 admixed with FliC, in which IL-4 and mainly IL-10 ap-
peared in higher concentrations than in nonimmunized mice or
mice vaccinated with FliC only. This picture changed consid-
erably when the same cytokines were measured in vaccinated
mice 2 months after the challenge with the Pb18 strain. The
IL-4 and IL-10 concentrations in mice immunized with gp43
were approximately 30% lower than the values detected in
nonimmunized animals, but the addition of FliC enhanced
production of cytokines to levels similar to those found in the
nonimmunized control group. Mice immunized with the re-
combinant hybrid P10/flagellins had IL-4 and IL-10 levels sim-
ilar to animals immunized only with gp43 or FliC. On the other
hand, mice immunized with FliC admixed with the synthetic
FIG. 2. Generation of recombinant hybrid flagellins genetically fused to the CD4 T-cell-specific gp43-derived P10 epitope. (A) Schematic
representation of the recombinant flagellins after P10 in-frame insertion at FliC central hypervariable domain. The two recombinant flagellins
carried the P10 peptide (FliCd-P10) or the P10 peptide with lysine residues on each side of the fusion site (FliCd-P10L). (B) Coomassie
blue-stained 12% polyacrylamide gel loaded with flagellins extracted from different Salmonella strains. Lane 1, molecular mass markers (Fer-
mentas); lane 2, FliCd flagellin extracted from S. Dublin strain SL5930 (with no insert); lane 3, FliCd-P10 flagellin extracted from S. Dublin strain
SLP10; lane 4, FliCd-P10L flagellin extracted from S. Dublin strain SLP10L; lane 5, purified gp43. Each well was loaded with approximately 2 g
of purified flagellins or gp43.
TABLE 2. Cytokine levels detected in lungs of mice immunized with different vaccine formulationsa
Vaccine group
Level (ng/ml) (mean 
 SD) of cytokine:
IL-4 IL-10 IL-12 IFN-	
BC AC BC AC BC AC BC AC
PBS 0.08 
 0.03 6.22 
 0.41 0.07 
 0.07 14.42 
 1.95 0.25 
 0.44 25.90 
 3.86 0.05 
 0.03 4.37 
 0.53
FliCd 1.50 
 0.24 2.93 
 0.64 2.76 
 0.29 7.52 
 1.97 5.33 
 1.34 22.00 
 1.56 1.23 
 0.07 9.96 
 1.08
gp43 0.20 
 0.01b 4.77 
 0.55b 0.18 
 0.10b 10.25 
 2.09 3.07 
 0.46b 30.07 
 1.44b 0.66 
 0.09b 12.62 
 0.44b
gp43  FliCd 3.01 
 0.82b 6.05 
 1.16b 4.10 
 0.39c 14.40 
 4.90b 7.46 
 0.46b 36.24 
 2.05c 2.25 
 0.49b 20.61 
 4.13c
FliCd-P10 0.82 
 0.56 3.21 
 0.83 2.39 
 0.15 9.48 
 2.30 4.38 
 0.97 30.67 
 3.10b 1.26 
 0.25 4.89 
 1.05
FliCd-P10L 0.60 
 0.30b 3.16 
 0.22 1.00 
 0.70b 8.95 
 0.93 3.65 
 0.83 22.76 
 2.26 0.44 
 0.06b 7.16 
 1.40b
P10  FliCd 1.50 
 0.49 2.80 
 0.06 1.47 
 0.88b 1.46 
 0.66b 9.40 
 0.86c 36.63 
 2.37c 2.35 
 0.19b 18.10 
 0.25b
a Immunization groups (5 to 8 animals/group) are as described in the legend to Fig. 2. BC, before challenge; AC, after challenge.
b P  0.05; statistically significant difference relative to that of mice immunized only with the FliCd flagellin.
c P  0.01; statistically significant difference relative to that of mice immunized only with the FliCd flagellin.
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P10 peptide had IL-4 and IL-10 values equal to those in non-
challenged vaccinated animals, which were statistically differ-
ent from the values in animals immunized only with FliC.
Measurements of IL-12 and IFN-	 in vaccinated mice
showed that all tested vaccines led to enhanced cytokine ex-
pression in lung cells, but statistically significant differences
with regard to nonimmunized animals were observed only in
animals immunized with gp43 and P10 admixed with FliC (Ta-
ble 2). Interestingly, there was no significant enhancement in
IL-12 and IFN-	 levels detected in mice immunized with the
recombinant flagellins compared to mice immunized only with
FliC, both before and after i.t. challenge with Pb18. However,
mice immunized with the P10 and FliC mixture, as well as
those immunized with gp43 plus FliC, produced enhanced
IL-12 and IFN-	 levels similar to those detected in mice im-
munized with gp43 admixed with FliC. On the other hand, the
IL-10 levels of P10 plus FliC-vaccinated mice remained lower
than those detected in mice immunized with FliC, particularly
after challenge with Pb18. Collectively, these data suggest that
the vaccine formulation based on P10 admixed with FliC in-
duced a predominant Th1 immune response compared to mice
immunized with the other tested vaccine formulations. Deter-
mination of the IFN-	/IL-4 (or IFN-	/IL-10) and IL-12/IL-4
(or IL-12/IL-10) ratios clearly demonstrated that mice immu-
nized with P10 admixed with FliC developed a more pro-
nounced Th1-biased immune response compared to animals
immunized with the other vaccine formulations (Fig. 3).
Growth of P. brasiliensis in lung tissues of mice vaccinated
with the different vaccine formulations. The protective effects
of the vaccine formulations were determined 2 months after
the i.t. challenge with the virulent Pb18 strain. CFU counts
were determined in homogenized lung tissue from vaccinated
animals as well as from nonimmunized mice and those inocu-
lated only with purified FliC (Fig. 4). In mice i.n. immunized
with gp43 only, there was a significant reduction in the number
of fungal colonies compared to the nonimmunized (PBS) or
the FliC-immunized groups, in agreement with previously de-
scribed results based on parenteral immunizations (37). Mice
immunized with gp43 admixed with FliC, however, showed
enhanced fungal proliferation in the lung tissues compared to
the nonimmunized (PBS) or the FliC-immunized groups. Mice
immunized with the hybrid flagellins (FliCd-P10 or FliCd-
P10L) showed a reduction in the number of viable yeast cells
similar to that observed in mice immunized with gp43 without
adjuvant. Furthermore, mice immunized with the vaccine for-
mulation prepared with the synthetic P10 peptide admixed
with FliC had a drastically reduced number of viable fungal
cells recovered from their lung tissues (100 CFU/g lung tis-
sue) 2 months after challenge with the Pb18 strain. In contrast
to mice immunized with gp43 or gp43 plus FliC, no viable yeast
cells were recovered from spleen and liver homogenates from
mice vaccinated with P10 admixed with FliC or the hybrid
flagellins (data not shown).
FIG. 3. Cytokine relative ratios measured in lungs of mice after challenge with the Pb18 strain. All cytokines were measured in whole extracts
of lung cells. Immunization groups and specific cytokine values used in the cytokine ratio determination were as depicted in Table 2.
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Histological analysis of lung tissue damage in immunized
mice challenged with P. brasiliensis. Histopathological analyses
of lung tissue samples collected from mice submitted to differ-
ent vaccine formulations showed that mice immunized with
gp43 admixed with FliC had extensive tissue destruction, with
abundant cellular infiltration (Fig. 5B). Exudative epithelioid
granulomas containing giant cells with multiplying fungal cells
were also observed in this vaccination group to a higher extent
than in nonimmunized animals (Fig. 5A). Mice immunized
with the hybrid recombinant FliCd-P10 and FliCd-P10L flagel-
lins showed lower numbers of exudative lesions than those
detected in animals immunized with FliC only or nonimmu-
nized animals (Fig. 5C). The number of visible, detectable, and
viable fungi was also lower than in the control groups. In
contrast, lung tissues of mice immunized with P10 admixed
with flagellin were virtually devoid of granulomas and viable
fungal cells. The lung tissues of mice immunized with P10 plus
FliC showed preserved alveolar organization with no indica-
tion of phagocytic cell infiltration (Fig. 5D).
DISCUSSION
In the present study, mucus-delivered vaccine formulations
based on the Salmonella FliC flagellin revealed contrasting, but
rather interesting, results regarding induction of specific im-
mune response and prophylactic protection against a virulent
P. brasiliensis strain in the murine model. While i.n. adminis-
tration of purified gp43 admixed with FliC induced a Th-2-
biased immune response, leading to exacerbated fungal multi-
plication and tissue damage, vaccine formulations based on
hybrid flagellins genetically fused with the gp43-derived P10
sequence, and mainly purified FliC admixed with synthetic P10
peptide, resulted in a Th1 predominant immune response and
enhanced protection to the fungal challenge in vaccinated
mice. The present evidence represents the first attempt to
develop experimental anti-PCM mucosal vaccines and extends
the knowledge about Salmonella flagellin adjuvant effects as-
sociated with different antigens.
The mucus-delivered vaccines have several advantages over
conventional parenteral vaccines. For example, mucosal vac-
cines are easier to administer, lack iatrogenic infection risks,
and more importantly, induce broader immunity, including
activation of both systemic and local immune responses, a
feature that may be particularly relevant for airborne infec-
tions. Therefore, the incorporation of Salmonella flagellin, a
potent adjuvant known to act both parenterally and at mucosal
sites, to P10-based vaccine formulations represented an alter-
native to the Freund adjuvant previously used in other anti-
PCM vaccines. Indeed, it opens a renewed perspective for a
future clinical use.
The epitope-based vaccine concept was designed as a strat-
egy to preserve antigen immunogenicity but avoid potential
undesirable effects, such as activation of suppressive immune
responses or induction of self-reacting antibodies (21). The low
immunogenicity of synthetic peptides, which represents a ma-
jor drawback in the development of effective peptide-based
vaccines, stimulated parallel experimental procedures, such as
the use of potent adjuvants, synthesis of tandem repeats or
MAPs, and genetic fusion with carrier proteins (25). In the
present study, we have shown that the combination of the
synthetic P10 peptide and the Salmonella FliC flagellin elicited
strong activation of CD4 T-cell-dependent immune re-
sponses leading to the efficient control of fungal infection in
vaccinated mice. The best results were achieved with the pep-
FIG. 5. Representative histopathology of lung lesions caused by P.
brasiliensis strain Pb18 in mice immunized with different vaccine for-
mulations. Tissue samples were collected 2 months after i.t. challenge
with strain Pb18. (A) Lung section from PBS-immunized mouse with
granuloma containing multiple viable fungal cells. (B) Lung section
from a mouse immunized with gp43 admixed with FliC. Observe the
extensive granulomatous lesions with intense cellular infiltration and
large number of multiplying fungal cells. (C) Lung section from mouse
immunized with the hybrid FliCd-P10L. (D) Lung section from mouse
immunized with P10 admixed with FliC showing preserved alveolar
structure and absence of granulomatous lesions and fungal cells. All
sections were amplified 40-fold and stained with hematoxylin-eosin.
FIG. 4. Detection of viable fungal cells in lung tissues of vaccinated
mice after i.t. challenge with P. brasiliensis Pb18. (A) Detection of
viable fungi in mice i.n. immunized with purified gp43 or gp43 admixed
with FliC. Immunization groups are as described in the legend to Fig.
2. (B) Detection of viable fungal cells in mice i.n. immunized with P10
epitope genetically fused with flagellin (FliCd-P10 or FliCd-P10L) or
synthetic P10 peptide admixed with FliC flagellin. PBS, mice immu-
nized only with PBS; FliCd, mice immunized only with FliC; FliCd-P10
and FliCd-P10L, mice immunized with purified recombinant FliCd-
P10 and FliCd-P10L, respectively; P10FliCd, mice immunized with
P10 admixed with FliCd. All mice groups were i.t. challenged with the
Pb18 strain and sacrificed 2 months later for determination of CFU in
homogenized lung tissue. The same experiments were repeated three
times. Each bar represents the medium number plus standard devia-
tion in organs collected from 8 to 10 animals in each group. Asterisks
indicate statistically significant differences between results detected in
mice immunized with gp43 and P10 and those in mice immunized only
with FliC (*, P  0.05; **, P  0.01).
VOL. 77, 2009 FLAGELLIN AS ADJUVANT FOR ANTI-P. BRASILIENSIS VACCINES 1705
tide admixed with the adjuvant, thus avoiding complex and
expensive chemical synthetic procedures or generation and
purification of hybrid peptides by genetic engineering methods.
The rather promiscuous binding of P10 to several major his-
tocompatibility complex class II molecules, both from mice and
humans (17, 37), in combination with the strong mucosal ad-
juvant effects of Salmonella flagellins resulted in enhanced
vaccine efficacy, leading to more efficient control of fungus
multiplication.
The genetic fusion of ovalbumin or the influenza virus M2
protein to Salmonella flagellins was required to generate anti-
gen-specific B- and T-cell-dependent responses (15, 16). In our
hands, coadministration of flagellin and the P10 peptide re-
sulted in a higher Th1-biased immune response than that in
mice immunized with hybrid flagellin genetically fused with
P10. Linking antigens to flagellin would supply in a single
molecule the signals required for activation and maturation of
APC, but the present results based on a mucus-delivered for-
mulation as well as other parenterally delivered vaccines (4,
23) clearly show that genetic fusion of flagellin to the target
antigen does not represent a requirement for proper stimula-
tion of the immune system by flagellin-containing vaccine
formulations.
Quantification of IFN-	 and IL-12 indicated that mice im-
munized with P10 admixed with FliC developed a more pro-
nounced Th1 immune response than mice immunized with the
recombinant hybrid flagellins (FliCd-P10 and FliCd-P10L).
Additionally, determination of the IFN-	/IL-4 and IFN-	/
IL-10 ratios (as well as the IL-12/IL-4 and IL-12/IL-10 ratios)
showed that mice immunized with FliC and P10 elicited a
predominant Th1 immune response to other immunization
groups, including mice immunized with gp43 and FliC and
those immunized with the recombinant hybrid P10-containing
flagellins. Indeed, induction of a Th1-biased immune response
positively correlated with asymptomatic and mild forms of
PCM in humans as well as resistance to P. brasiliensis infection
in mice (9, 22, 26, 32). Additionally, the lack of anti-gp43
antibodies in animals immunized with the P10/FliC formula-
tion further showed that immunization with P10 peptide avoids
other gp43 sequences involved in nonprotective anti-P. brasil-
iensis immune responses. The possibility to add another gp43-
derived peptide, which reacts with a protective monoclonal
antibody (7), may further enhance the efficacy of the vaccine
formulation by means of a proper Th1 response in combina-
tion with a protective antibody response.
Innate immunity has a pivotal role on the control of P.
brasiliensis replication, as well as other microbial pathogens, in
different mammalian hosts (8). TLR ligands directly interact
with macrophages and dendritic cells, leading to inflammatory
responses required for the direct elimination of the pathogen
and generation of protective adaptive responses. In this study,
we demonstrated that incorporation of Salmonella FliC, a
TLR-5 ligand, may trigger anti-PCM immune responses rang-
ing from complete prophylactic protection to exacerbated par-
asite multiplication according to the nature of the antigen
tested, thus offering new tools for the understanding of the
immunological mechanisms leading to resistance or sensitivity
to P. brasiliensis. In addition, the evidence that the immuno-
genicity of epitope-based vaccines, when associated with Sal-
monella FliC, may elicit a protective immune response in vac-
cinated mice raises new perspectives for the development of
improved vaccine formulations and warrants further studies
aimed at the prophylactic and therapeutic control of PCM.
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